EMZOTAMIG
UNII WQN6EJ3AH6
Substance Identification & Data
This profile provides standardized clinical and technical data for Emzotamig, uniquely identified by the FDA Unique Ingredient Identifier (UNII) WQN6EJ3AH6.
Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 3037572-57-6 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.
WQN6EJ3AH6
3037572-57-6
N/A
Detailed Substance Profile
Preferred Name
EMZOTAMIG
Official standardized name for this substance within the FDA UNII nomenclature system.
NCI Thesaurus
National Cancer Institute reference terminology for clinical and research data.
INN ID
13697
Sequential identifier assigned via the WHO International Nonproprietary Name program.
Substance Type
Emzotamig
ISO 11238 classification category (e.g., Chemical, Polymer, Protein).
Synonyms and Nomenclature
This section provides a complete list of nomenclature and identifier mappings for Emzotamig. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.
FDA Official Name
Emzotamig
Common Names & Synonyms
Immunoglobulin G1, bispecific, anti-(human natural cytotoxicity triggering receptor 1) (human-Mus musculus monoclonal 3D9-H1L1 heavy chain variable region) fusion protein with immunoglobulin anti-(human tumor necrosis factor receptor superfamily protein TNFRSF17) (human-Mus musculus monoclonal CA10v7 heavy chain variable region) fusion protein with immunoglobulin G1 [119-alanine,122-aspartic acid,175-cysteine,185-cysteine,215-glutamic acid,237-cysteine,249-tryptophan,de-C-terminal lysine] (human γ1-chain constant region), (348→343′)-disulfide with immunoglobulin anti-(human tumor necrosis factor receptor superfamily protein TNFRSF17) (human-Mus musculus monoclonal CA10v7 light chain variable region) fusion protein with peptide linker (GGGGS)2 fusion protein with immunoglobulin anti-(human natural cytotoxicity triggering receptor 1) (human-Mus musculus monoclonal 3D9-H1L1 light chain variable region) fusion protein with peptide linker (GGGGS)2 fusion protein with immunoglobulin (human κ-chain constant region), (354→6"),(357→9")-bis(disulfide) with immunoglobulin G1 [16-alanine, 19-aspartic acid,72-cysteine,82-cysteine,112-glutamic acid,129-cysteine,146-serine,148-alanine,187-valine,215-arginine,216-phenylalanine,de-C-terminal lysine] (human γ1-chain hinge-CH2-CH3 fragment)
VH-(H-gamma1) heavy chain anti-NCR1 and anti-TNFRSF7 (H) (1-574) knob [VH anti-NCR1 humanized (Homo sapiens IGHV1-69*08 (83.7%) -(IGHD) -IGHJ4*01 (92.3%) L123>T (115), CDR-IMGT [8.8.13] (26-33.51-58.97-109)) (1-120) -H-gamma1 anti-TNFRSF7 humanized (121-574) (VH anti-TNFRSF7 humanized (Homo sapiens IGHV3-33*01 (86.7%) -(IGHD) -IGHJ5*02 (100%), CDR-IMGT [8.8.18] (146-153.171-178.217-234)) (121-245) -Homo sapiens IGHG1*01, G1m17,1 CH1 K120, CH3 D12, L14, 3-G1v13 CH2 A1.1, D3, E117, 11-G1v54 CH2 C83, C85, 14-G1v74 CH3 C10, 14-G1v32 CH3 W22 (knob) (CH1 K120 (342) (246-343), hinge 1-15 (344-358), CH2 G1.1>A (364), S3>D (367), R83>C (420), V85>C (430), I117>E (460) (359-468), CH3 S10>C (482), D12 (484), L14 (486), T22>W (494) (469-573), CHS K2>del (574)) (246-574))], (348-343')-disulfide with V-lambda-10mer-V-kappa-10mer-C-kappa anti-TNFRSF17 and anti-NCR1 (L') (1'-343') [V-LAMBDA anti-TNFRSF17 humanized (Homo sapiens IGLV7-43*01 (77.9%) -IGLJ3*02 (100%), CDR-IMGT [9.3.9] (26'-34'.52'-54'.91'-99')) (1'-109') -10-mer bis(tetraglycyl-seryl) linker (110'-119') -V-KAPPA anti-NCR1 humanized (Homo sapiens IGKV1-33*01 (88.4%) -IGKJ4*01 (100%), CDR-IMGT [6.3.9] (146'-151'.169'-171'.208'-216')) (120'-226') -10-mer bis(tetraglycyl-seryl) linker (227'-236') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (282'), V101 (320')) (237'-343')]; G1(h-CH2-CH3) heavy chain (H'') (1''-226'') hole [Homo sapiens IGHG1*01, G1m17,1 CH3 D12, L14, 3-G1v13 CH2 A1.1, D3, E117, 11-G1v54 CH2 C83, C85, 14-G1v75 CH3 C5, 14-G1v33 CH3 S22, A24, V86 (hole), 10-G1v83 CH3 R115, F116 (hinge 6-15 (1''-10''), CH2 G1.1>A (16''), S3>D (19''), R83>C (72''), V85>C (82''), I117>E (112'') (11''-120''), CH3 Y5>C (129''), D12 (136''), L14 (138''), T22>S (146''), L24>A (148''), Y86>V (187''), H115>R (215''), Y116>F (216'') (121''-225''), CHS K2>del (226'')) (1''-226'')]; dimer (354-6'':357-9'':482-129'')-trisdisulfide, produced in a cell line from Chinese hamster ovary (CHO) cells, derived from the cell line CHO-K1, glycoform alfa
emzotamig [INN]
immunoglobulin [VH-(H-gamma1)_ V-lambda-10mer-V-kappa-10mer-C-kappa)]_G1(h-CH2-CH3), anti-[Homo sapiens NCR1 (natural cytotoxicity triggering receptor 1, NKP46, NKp46, NK cell-activating receptor, LY94, CD335)], anti-[Homo sapiens TNFRSF17 (tumor necrosis factor (TNF) receptor superfamily member 17, B cell maturation antigen, BCMA, TNFRSF13A, CD269)], humanized monoclonal antibody, bispecific, bivalent (Emzotamig)
